Notably, treatment with cabozantinib increases the expression of major histocompatibility complex (MHC) class I antigens in MC38-CEA mouse tumor cells and the number of peripheral CD8 + T-cells while decreasing the number of Tregs and MDSCs in a MC38CEA mouse colon cancer model [42]. This evidence concerns the gene CD8A and malignant colon neoplasm.